598 related articles for article (PubMed ID: 17462628)
41. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
42. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Rieger J; Frank B; Weller M; Wick W
Cell Physiol Biochem; 2007; 20(1-4):23-34. PubMed ID: 17595512
[TBL] [Abstract][Full Text] [Related]
44. A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms.
Picarda G; Surget S; Guiho R; Téletchéa S; Berreur M; Tirode F; Pellat-Deceunynck C; Heymann D; Trichet V; Rédini F
Mol Cancer Res; 2012 Mar; 10(3):336-46. PubMed ID: 22258765
[TBL] [Abstract][Full Text] [Related]
45. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
46. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
47. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
48. Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells.
Zhu ZC; Liu JW; Yang C; Li MJ; Wu RJ; Xiong ZQ
Cell Death Dis; 2019 Feb; 10(2):118. PubMed ID: 30742128
[TBL] [Abstract][Full Text] [Related]
49. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
[TBL] [Abstract][Full Text] [Related]
50. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H
Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636
[TBL] [Abstract][Full Text] [Related]
51. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells.
Hao C; Beguinot F; Condorelli G; Trencia A; Van Meir EG; Yong VW; Parney IF; Roa WH; Petruk KC
Cancer Res; 2001 Feb; 61(3):1162-70. PubMed ID: 11221847
[TBL] [Abstract][Full Text] [Related]
52. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.
Kim YH; Lee YJ
J Cell Biochem; 2007 Mar; 100(4):998-1009. PubMed ID: 17031854
[TBL] [Abstract][Full Text] [Related]
53. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
54. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
Bouralexis S; Findlay DM; Atkins GJ; Labrinidis A; Hay S; Evdokiou A
Br J Cancer; 2003 Jul; 89(1):206-14. PubMed ID: 12838325
[TBL] [Abstract][Full Text] [Related]
55. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines.
Yoshida S; Narita T; Koshida S; Ohta S; Takeuchi Y
Pediatr Res; 2003 Nov; 54(5):709-17. PubMed ID: 12904602
[TBL] [Abstract][Full Text] [Related]
56. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.
Wang X; Chen W; Zeng W; Bai L; Tesfaigzi Y; Belinsky SA; Lin Y
Mol Cancer Ther; 2008 May; 7(5):1156-63. PubMed ID: 18483303
[TBL] [Abstract][Full Text] [Related]
57. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
Suliman A; Lam A; Datta R; Srivastava RK
Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
[TBL] [Abstract][Full Text] [Related]
58. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
[TBL] [Abstract][Full Text] [Related]
59. Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a novel Akt/NF-κB signalling inhibitor.
Omar HA; Arafa el-SA; Maghrabi IA; Weng JR
Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):464-71. PubMed ID: 24401154
[TBL] [Abstract][Full Text] [Related]
60. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Abdulghani J; Allen JE; Dicker DT; Liu YY; Goldenberg D; Smith CD; Humphreys R; El-Deiry WS
PLoS One; 2013; 8(9):e75414. PubMed ID: 24086526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]